Infliximab Increases Triglyceride Levels in Psoriatic Arthritis Patients
Author Information
Author(s): Karla R. Castro, Nádia E. Aikawa, Carla Gonçalves Saad, Júlio C. B. Moraes, Ana C. Medeiros, Licia Maria H. Mota, Clovis A. A. Silva, Eloísa Bonfá, Jozélio F. Carvalho
Primary Institution: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Hypothesis
Does anti-TNF therapy affect lipid profiles in patients with psoriatic arthritis?
Conclusion
Anti-TNF therapy may increase triglyceride and VLDL levels in psoriatic arthritis patients after three months.
Supporting Evidence
- Triglyceride levels increased from 117.8 mg/dL to 140.1 mg/dL after three months.
- VLDL-c levels increased from 23.6 mg/dL to 28.4 mg/dL after three months.
- No significant changes were observed in total cholesterol, LDL-c, or HDL-c levels.
Takeaway
This study found that a medicine called infliximab can make fat levels in the blood go up for people with a skin and joint disease called psoriatic arthritis.
Methodology
Fifteen patients with psoriatic arthritis were treated with infliximab and their lipid profiles were measured before and after three months of treatment.
Limitations
The study had a small sample size and excluded patients with prior dyslipidemia or other conditions affecting lipid metabolism.
Participant Demographics
Mean age of participants was 41.9 years, 53% were male, and 93% were Caucasian.
Statistical Information
P-Value
0.028 for triglycerides, 0.019 for VLDL-c
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website